The Royal Society and the Academy of Medical Sciences have announced their new Fellows list for 2021. The BSI would like to extend our congratulations to the outstanding immunologists recognised as Fellows.
Academy of Medical Sciences Fellows
Professor Sarah Gilbert, Professor of Vaccinology, Jenner Institute & Nuffield Department of Clinical Medicine, University of Oxford. Professor Gilbert has been making and testing vaccines designed to induce T cell responses for over ten years, chiefly using antigens from malaria and influenza. Sarah led the team which developed the Oxford-AstraZeneca vaccine against SARS-CoV-2. She is a co-founder of the University of Oxford's spin-out company Vaccitech, which is developing novel vaccines using the non-replicating viral vectors Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA).
Professor Beate Kampmann, Director, The Vaccine Centre, and Professor of Paediatric Infection and Immunity, London School of Hygiene and Tropical Medicine. Professor Kampmann's main area of research is paediatric tuberculosis, including HIV co-infection and vaccinology. Her team also works to understand age-related immune responses to infection and vaccination and is developing novel strategies for prevention of infection in the newborn, such as maternal immunisation. Beate heads the Vaccinology theme at the MRC-The Gambia, where she leads a team of over 80 scientists and support staff to conduct research and clinical trials in tuberculosis, infant immunology and molecular diagnostics aimed at improving global health with a particular emphasis on maternal and child health in West Africa.
Professor Adrian Liston, Senior Group Leader, Babraham Institute. Professor Liston's laboratory aims to understand how regulatory T cells migrate to tissues and what controls their numbers and their functions, both immunological and tissue homeostatic in nature. His team has extensive experience in the fields of autoimmune genetics, diabetes, primary immunodeficiencies, the thymus and regulatory T cells. Adrian has been awarded the Francqui Chair, Eppendorf Prize and three ERC grants, among other honours.
Professor Anna Katharina (Katja) Simon, Professor of Immunology, Kennedy Institute of Rheumatology, University of Oxford. Professor Simon studies cell fate in the haematopoietic system. Her work has revolutionised the field of autophagy, the main conserved cellular bulk degradation pathway. Her group discovered that autophagy maintains healthy red blood cells, stem cells and memory T cells and promotes differentiation while preventing ageing of the hematopoietic system. In 2018, Katja was awarded the prestigious EFIS-EJI Ita Askonas Prize, which recognises prominent European female group leaders in immunology.
Dr Jane Osbourn, CSO, Alchemab Therapeutics. Dr Osbourn is a leader in the field of antibody engineering and has over 30 years’ experience in biotechnology. She has made a significant contribution to the to the development of antibody phage display technology and contributed to the discovery and development of eight marketed drugs. Jane is currently a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and in 2019, she was awarded an OBE in the Queen’s birthday honours for services to drug discovery, development and biotechnology.
Royal Society Fellows
Professor Adrian Hill, Lakshmi Mittal and Family Professor of Vaccinology and Director, The Jenner Institute, Nuffield Department of Medicine, University of Oxford. Professor Hill founded and directs the Jenner Institute at Oxford University, one of the leading academic vaccine institutes globally. The Jenner Institute focuses on designing and developing vaccines for infectious diseases prevalent in developing countries, such as HIV/AIDS, malaria and tuberculosis. He also heads a group at the Wellcome Trust Centre for Human Genetics which studies genetic susceptibility factors for common bacterial diseases. His research career began with work on HLA polymorphism and malaria susceptibility in West Africa that led to an interest in vaccine design and development. Most recently, Adrian led the development team behind the Oxford-AstraZeneca COVID-19 vaccine.